Harvard-Led Researchers Pursuing Innovative, Non-Toxic IBD Treatment

Apr 13, 2019 | IBD, Myosin Light Chain Kinase (MLCK)

Researchers from Harvard Medical School First Affiliated Hospital of Soochow University and the University of Chicago are in hot pursuit of an innovative, non-toxic method to explore Irritable Bowel Disease as well as other conditions that impact gastrointestinal issues in the human body.

The team, led by Harvard’s Jerrold Turner, are targeting a Myosin Light Chain Kinase (MLCK) that can cure and prevent IBD and all other gastrointestinal issues as reported by Industry News Focus. Apparently, MLCK plays a significant role that causes gastronomical inflammation as it directly acts and prevents such problems.  Their research reveals that Divertin diverts MCLK1 from the place where it acts on the epithelial layer.  Moreover, divertin works on models that have IBD and diarrhea. For example, Divertin prevents damages in the epithelial layer without hindering the work of MLCK in performing its maintenance work.  Researchers believe that this discovery represents a non-toxic and novel approach to restoring the epithelial barrier as well as potential cure of IBD.

Lead Research/Investigator

Jerrold Turner


Pin It on Pinterest